Magazine: The GLP-1 shortage is over. What’s next for compounders?
The astronomical rise in popularity of GLP-1RAs in recent years has led to a shortage, prompting users to turn to…
Features
Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
FDA layoffs and priority review programme’s lapse disrupt rare disease pipeline
The GLP-1 drug shortage is over. What’s next for the compounders?
Can AI replace medical writers? Experts say not immediately
IRA holds the scope to shape pharma’s research strategy, say experts
Magazine: Are European biopharma manufacturers ‘nearshoring’?
Big pharma faces headwinds in China as vaccine sales decline
